Cargando…

A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy

INTRODUCTION: Image guidance with gold fiducials improves outcomes of prostate radiotherapy. However, gold produces artefact on CT imaging, interfering with contouring and verification. The purpose of this study was to compare polymer to standard gold fiducials using radiotherapy imaging modalities...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim Joon, Daryl, Berry, Colleen, Harris, Benjamin, Tacey, Mark, Smith, Drew, Lawrentschuk, Nathan, Schneider, Michal Elisabeth, Fraser, Olivia, Hall, Megan, Chao, Michael, Foroudi, Farshad, Jenkins, Trish, Angus, David, Wada, Morikatsu, Sengupta, Shomik, Khoo, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930895/
https://www.ncbi.nlm.nih.gov/pubmed/36818674
http://dx.doi.org/10.3389/fonc.2022.1023288
_version_ 1784889128061501440
author Lim Joon, Daryl
Berry, Colleen
Harris, Benjamin
Tacey, Mark
Smith, Drew
Lawrentschuk, Nathan
Schneider, Michal Elisabeth
Fraser, Olivia
Hall, Megan
Chao, Michael
Foroudi, Farshad
Jenkins, Trish
Angus, David
Wada, Morikatsu
Sengupta, Shomik
Khoo, Vincent
author_facet Lim Joon, Daryl
Berry, Colleen
Harris, Benjamin
Tacey, Mark
Smith, Drew
Lawrentschuk, Nathan
Schneider, Michal Elisabeth
Fraser, Olivia
Hall, Megan
Chao, Michael
Foroudi, Farshad
Jenkins, Trish
Angus, David
Wada, Morikatsu
Sengupta, Shomik
Khoo, Vincent
author_sort Lim Joon, Daryl
collection PubMed
description INTRODUCTION: Image guidance with gold fiducials improves outcomes of prostate radiotherapy. However, gold produces artefact on CT imaging, interfering with contouring and verification. The purpose of this study was to compare polymer to standard gold fiducials using radiotherapy imaging modalities to assess the visibility and artefact. METHODS: Twenty eight patients with locally advanced prostate cancer were enrolled, half had three polymer fiducials implanted into the prostate and half underwent insertion of gold fiducials. Patients were imaged with CT, T2 weighted MRI, cone-beam CT (CBCT) and planar KV images. Fiducials were scored for visibility and assessed for CT artefact in surrounding prostate tissue. The artefact was quantified from Hounsfield number histograms and separated into percentile ranges and proportion of voxels in HU normal tissue range of a 2cm sphere surrounding the fiducial. RESULTS: Gold and polymer fiducials were sufficiently visible for CT and CBCT verification. The gold fiducials could be visualized well on KV planar imaging; however, the polymer markers were obscured by pelvic bones. Neither polymer nor gold fiducials could be visualized on MRI. The polymer fiducial produced less artefact than gold on CT, having less voxel spread for the HU percentile ranges and a greater proportion of voxels in the normal tissue range. CONCLUSIONS: Polymer fiducials are a more suitable fiducial than gold for CT/CBCT in prostate cancer radiotherapy, demonstrating minimal artefact and good visibility on CT. However, they were not well seen on MRI or KV imaging and thus not suitable for co-registration or planar KV verification.
format Online
Article
Text
id pubmed-9930895
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99308952023-02-16 A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy Lim Joon, Daryl Berry, Colleen Harris, Benjamin Tacey, Mark Smith, Drew Lawrentschuk, Nathan Schneider, Michal Elisabeth Fraser, Olivia Hall, Megan Chao, Michael Foroudi, Farshad Jenkins, Trish Angus, David Wada, Morikatsu Sengupta, Shomik Khoo, Vincent Front Oncol Oncology INTRODUCTION: Image guidance with gold fiducials improves outcomes of prostate radiotherapy. However, gold produces artefact on CT imaging, interfering with contouring and verification. The purpose of this study was to compare polymer to standard gold fiducials using radiotherapy imaging modalities to assess the visibility and artefact. METHODS: Twenty eight patients with locally advanced prostate cancer were enrolled, half had three polymer fiducials implanted into the prostate and half underwent insertion of gold fiducials. Patients were imaged with CT, T2 weighted MRI, cone-beam CT (CBCT) and planar KV images. Fiducials were scored for visibility and assessed for CT artefact in surrounding prostate tissue. The artefact was quantified from Hounsfield number histograms and separated into percentile ranges and proportion of voxels in HU normal tissue range of a 2cm sphere surrounding the fiducial. RESULTS: Gold and polymer fiducials were sufficiently visible for CT and CBCT verification. The gold fiducials could be visualized well on KV planar imaging; however, the polymer markers were obscured by pelvic bones. Neither polymer nor gold fiducials could be visualized on MRI. The polymer fiducial produced less artefact than gold on CT, having less voxel spread for the HU percentile ranges and a greater proportion of voxels in the normal tissue range. CONCLUSIONS: Polymer fiducials are a more suitable fiducial than gold for CT/CBCT in prostate cancer radiotherapy, demonstrating minimal artefact and good visibility on CT. However, they were not well seen on MRI or KV imaging and thus not suitable for co-registration or planar KV verification. Frontiers Media S.A. 2023-02-01 /pmc/articles/PMC9930895/ /pubmed/36818674 http://dx.doi.org/10.3389/fonc.2022.1023288 Text en Copyright © 2023 Lim Joon, Berry, Harris, Tacey, Smith, Lawrentschuk, Schneider, Fraser, Hall, Chao, Foroudi, Jenkins, Angus, Wada, Sengupta and Khoo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lim Joon, Daryl
Berry, Colleen
Harris, Benjamin
Tacey, Mark
Smith, Drew
Lawrentschuk, Nathan
Schneider, Michal Elisabeth
Fraser, Olivia
Hall, Megan
Chao, Michael
Foroudi, Farshad
Jenkins, Trish
Angus, David
Wada, Morikatsu
Sengupta, Shomik
Khoo, Vincent
A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy
title A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy
title_full A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy
title_fullStr A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy
title_full_unstemmed A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy
title_short A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy
title_sort clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930895/
https://www.ncbi.nlm.nih.gov/pubmed/36818674
http://dx.doi.org/10.3389/fonc.2022.1023288
work_keys_str_mv AT limjoondaryl aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT berrycolleen aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT harrisbenjamin aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT taceymark aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT smithdrew aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT lawrentschuknathan aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT schneidermichalelisabeth aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT fraserolivia aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT hallmegan aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT chaomichael aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT foroudifarshad aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT jenkinstrish aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT angusdavid aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT wadamorikatsu aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT senguptashomik aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT khoovincent aclinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT limjoondaryl clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT berrycolleen clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT harrisbenjamin clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT taceymark clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT smithdrew clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT lawrentschuknathan clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT schneidermichalelisabeth clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT fraserolivia clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT hallmegan clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT chaomichael clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT foroudifarshad clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT jenkinstrish clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT angusdavid clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT wadamorikatsu clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT senguptashomik clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy
AT khoovincent clinicalstudycomparingpolymerandgoldfiducialsforprostatecancerradiotherapy